²é¿´: 1893  |  »Ø¸´: 5

Áîºü³å?ÛСÐÜ

ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)

ħµÀÊ¥¾ý

[½»Á÷] ¡¾2015ÄêFDAÅú×¼ÐÂÒ©»ã×Ü¡¿ ÒÑÓÐ4È˲ÎÓë

FDA Approved new Drugs in 2015


                                                                                                                                                                           date time£º2015-2-10
Cardiology/Vascular Diseases
Prestalia (perindopril arginine and amlodipine besylate); Symplmed Pharmaceuticals; For the treatment of hypertension, Approved January 2015

Savaysa (edoxaban); Daiichi Sankyo; For the treatment of deep vein thrombosis, pulmonary embolism and risk of stroke and embolism due to atrial fibrillation, Approved January 2015

Dermatology
Cosentyx (secukinumab); Novartis; For the treatment of plaque psoriasis, Approved January 2015

Endocrinology
Natpara (parathyroid hormone) ; NPS Pharmaceuticals; For the control hypocalcemia in patients with hypoparathyroidism, Approved January 2015

Family Medicine
Cosentyx (secukinumab); Novartis; For the treatment of plaque psoriasis, Approved January 2015

Savaysa (edoxaban); Daiichi Sankyo; For the treatment of deep vein thrombosis, pulmonary embolism and risk of stroke and embolism due to atrial fibrillation, Approved January 2015

Hematology
Natpara (parathyroid hormone) ; NPS Pharmaceuticals; For the control hypocalcemia in patients with hypoparathyroidism, Approved January 2015

Immunology
Cosentyx (secukinumab); Novartis; For the treatment of plaque psoriasis, Approved January 2015

Evotaz (atazanavir and cobicistat) ; Bristol-Myers Squibb; For the treatment of HIV-1 infection, Approved January 2015

Prezcobix (darunavir and cobicistat); Janssen; For the treatment of HIV-1 infection, Approved January 2015

Infections and Infectious Diseases
Bexsero (Meningococcal Group B Vaccine); Novartis; For the treatment of invasive meningococcal disease caused by serogroup B, Approved January 2015

Evotaz (atazanavir and cobicistat) ; Bristol-Myers Squibb; For the treatment of HIV-1 infection, Approved January 2015

Prezcobix (darunavir and cobicistat); Janssen; For the treatment of HIV-1 infection, Approved January 2015

Neurology
Duopa (carbidopa and levodopa) enteral suspension ; Abbvie; For the treatment of motor fluctuations in patients with advanced Parkinson's disease, Approved January 2015

Rytary (carbidopa and levodopa) extended-release capsules; Impax Labs; For the treatment of Parkinson's disease, Approved January 2015

Obstetrics/Gynecology (Women¡¯s Health)
Ibrance (palbociclib); Pfizer; For the treatment of ER-positive, HER2-negative breast cancer, Approved February 2015

Oncology
Ibrance (palbociclib); Pfizer; For the treatment of ER-positive, HER2-negative breast cancer, Approved February 2015

Pediatrics/Neonatology
Bexsero (Meningococcal Group B Vaccine); Novartis; For the treatment of invasive meningococcal disease caused by serogroup B, Approved January 2015

Vaccines
Bexsero (Meningococcal Group B Vaccine); Novartis; For the treatment of invasive meningococcal disease caused by serogroup B, Approved January 2015
»Ø¸´´ËÂ¥

» ÊÕ¼±¾ÌûµÄÌÔÌûר¼­ÍƼö

ò§çïҩѧ żµÄ

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

¾ý×Ó²ØÆ÷ÓÚÉí£¬´ýʱ¶ø¶¯£¡
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

³ô±¿±¿

ľ³æ (ÕýʽдÊÖ)

°ô°ô

[ ·¢×ÔÊÖ»ú°æ http://muchong.com/3g ]
2Â¥2015-02-10 19:46:47
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ÁèÓîÀ׳Ø

³¬¼¶°æÖ÷ (ÎÄѧ̩¶·)

Сľ³æ¿ÆÑдóʹ\(^o^)/~

ÓÅÐãÇø³¤ÓÅÐãÇø³¤ÓÅÐãÇø³¤ÓÅÐãÇø³¤ÓÅÐãÇø³¤ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

лл·ÖÏí\(^o^)/~
ÉÏÉÆÈôË®\(^o^)/~2025\(^o^)/~
3Â¥2015-02-11 08:30:25
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

myktt

ÖÁ×ðľ³æ (ÖøÃûдÊÖ)

º¢Ëûµù

лл£¬ÊÕµ½ÁË
ºÏ³ÉÀϰÖ
4Â¥2015-02-11 15:22:14
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

gatzz_0827

½ð³æ (ÕýʽдÊÖ)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
Ibrance (palbociclib); Pfizer; For the treatment of ER-positive, HER2-negative breast cancer, Approved February 2015
´óÅúÇÀ·Â¹«Ë¾¿ªÊ¼¼¦¶³ÁË
5Â¥2015-02-12 09:17:37
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

Áîºü³å?ÛСÐÜ

ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)

ħµÀÊ¥¾ý

ÒýÓûØÌû:
5Â¥: Originally posted by gatzz_0827 at 2015-02-12 09:17:37
Ibrance (palbociclib); Pfizer; For the treatment of ER-positive, HER2-negative breast cancer, Approved February 2015
´óÅúÇÀ·Â¹«Ë¾¿ªÊ¼¼¦¶³ÁË

¶¯×÷¿ìµÄ£¬Ó¦¸ÃÔÚÈýÆÚÁÙ´²Ê±¾Í¿ª¶¯ÁË
¾ý×Ó²ØÆ÷ÓÚÉí£¬´ýʱ¶ø¶¯£¡
6Â¥2015-02-12 09:40:05
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ Áîºü³å?ÛСÐÜ µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 276Çóµ÷¼Á +4 ·lyh123 2026-02-28 5/250 2026-03-02 11:20 by yuchj
[¿¼ÑÐ] ²ÄÁϹ¤³Ìר˶283Çóµ÷¼Á 5+4 £¬£¡£¿ 2026-03-02 6/300 2026-03-02 11:07 by ºÚ£¡ÔÚ¸ÉÂï
[¿¼ÑÐ] 281Çóµ÷¼Á +5 2026¼ÆËã»ú_³ÏÐÄ 2026-03-01 8/400 2026-03-02 11:05 by Íô£¡£¿£¡
[¿¼ÑÐ] Çóµ÷¼Á +8 yunziaaaaa 2026-03-01 9/450 2026-03-02 11:03 by ºÚ£¡ÔÚ¸ÉÂï
[¿¼ÑÐ] 264Çóµ÷¼Á +4 °ÍÀ­°ÍÀ­¸ù556 2026-02-28 4/200 2026-03-02 10:48 by yuchj
[¿¼ÑÐ] 0856²ÄÁϵ÷¼Á +4 ÑØ°¶Óб´¿ÇOUC 2026-03-02 4/200 2026-03-02 10:19 by ¹«èªåÐÒ£
[¿¼ÑÐ] 282Çóµ÷¼Á +3 2103240126 2026-03-02 4/200 2026-03-02 09:25 by Íô£¡£¿£¡
[¿¼ÑÐ] 0857µ÷¼Á +4 Ò»ll°ë 2026-02-28 5/250 2026-03-02 02:33 by 908055542
[¿¼ÑÐ] 272Çóµ÷¼Á +6 ÌïÖÇÓÑ 2026-02-28 6/300 2026-03-01 21:40 by ¹«èªåÐÒ£
[¿¼ÑÐ] 299Çóµ÷¼Á +3 YÄ«Ã÷ÆåÃîY 2026-02-28 5/250 2026-03-01 21:01 by tangxiaotian
[¿¼ÑÐ] »¯¹¤299·ÖÇóµ÷¼Á Ò»Ö¾Ô¸985Âä°ñ +5 ÎûÎû(*^¦Ø^*) 2026-03-01 5/250 2026-03-01 19:47 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] Ò»Ö¾Ô¸ÖÐÄÏ´óѧÀíѧ»¯Ñ§ +4 15779376950 2026-03-01 5/250 2026-03-01 19:00 by Fff-1
[¿¼ÑÐ] 328Çóµ÷¼Á +3 aaadim 2026-03-01 5/250 2026-03-01 17:29 by njzyff
[¿¼ÑÐ] 0856²ÄÁÏÇóµ÷¼Á +4 ÂéÀ±öÏÓã 2026-02-28 4/200 2026-03-01 16:51 by caszguilin
[¿¼ÑÐ] 307Çóµ÷¼Á +5 wyyyqx 2026-03-01 5/250 2026-03-01 15:21 by Fff-1
[¿¼ÑÐ] 304Çóµ÷¼Á +6 ÂüÊâ2266 2026-02-28 7/350 2026-03-01 15:14 by wjLi2017
[¿¼ÑÐ] Çóµ÷¼Á +6 repeatt?t 2026-02-28 6/300 2026-03-01 14:37 by Sakura»æ
[¿¼ÑÐ] ²ÄÁÏ284Çóµ÷¼Á£¬Ò»Ö¾Ô¸Ö£ÖÝ´óѧӢһÊý¶þר˶ +10 ÏëÉϰ¶µÄÍÁ²¦Êó 2026-02-28 10/500 2026-03-01 14:12 by yc258
[¿¼ÑÐ] 085600²ÄÁϹ¤³ÌÒ»Ö¾Ô¸Öпƴó×Ü·Ö312Çóµ÷¼Á +8 ³ÔÏüÒ¹1 2026-02-28 10/500 2026-02-28 20:27 by L135790
[¸ß·Ö×Ó] Çó»·ÑõÊ÷Ö¬Ñз¢1Ãû +3 Ëïxc 2026-02-25 11/550 2026-02-28 16:57 by ichall
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û